Revenue Performance - Storz & Bickel net revenue increased by 32% year-over-year to $16 million in Q2 FY2025, driven by strong growth in Germany and the U.S.[7] - Canada cannabis net revenue was $37 million in Q2 FY2025, an 8% decrease compared to Q2 FY2024, with medical cannabis increasing by 16% while adult-use cannabis declined by 24%[5][9] - International markets net revenue rose by 12% to $10 million in Q2 FY2025, with significant growth in Poland and Germany[6] - Canopy Growth reported net revenue of $62.99 million for the three months ended September 30, 2024, a decrease of 9.3% from $69.60 million in the same period last year[22] - Net revenue for the three months ended September 30, 2024, was $62,991, a decrease of 9% from $69,595 in the same period of 2023[25] - The Canada cannabis segment reported net revenue of $37,077 for the three months ended September 30, 2024, down from $40,266 in the same period of 2023[28] - The international markets cannabis segment revenue increased to $10,060 for the three months ended September 30, 2024, compared to $8,977 in the same period of 2023[28] - The Storz & Bickel segment generated revenue of $15,854 for the three months ended September 30, 2024, up from $11,991 in the same period of 2023[28] Financial Metrics - Consolidated gross margin improved by 100 basis points to 35% in Q2 FY2025, attributed to cost savings and a shift to higher-margin medical cannabis sales[2] - International cannabis gross margins increased by 1,700 basis points to 47% in Q2 FY2025, driven by a favorable sales mix[6] - The company's gross margin for the quarter was $21.84 million, representing a gross margin percentage of approximately 34.7%, down from $23.43 million in the prior year[22] - Gross margin for the three months ended September 30, 2024, was $21,838, representing a gross margin percentage of 35%, compared to 33% in the prior year[25] - Adjusted EBITDA loss was $6 million in Q2 FY2025, representing a 54% improvement year-over-year[2] - Adjusted EBITDA for the three months ended September 30, 2024, was $(5,507), compared to $(11,856) in the same period of 2023, indicating a reduction in losses[26] Cash Flow and Liquidity - Free cash flow outflow was $56 million in Q2 FY2025, a 16% improvement compared to Q2 FY2024, primarily due to reduced cash interest expenses[2] - Cash and short-term investments increased to $231 million at September 30, 2024, up from $195 million at June 30, 2024[2] - Cash and cash equivalents increased to $228.42 million from $170.30 million, indicating improved liquidity[20] - Cash and cash equivalents at the end of the period were $228,416, compared to $242,975 at the end of the previous year[24] - Net cash used in operating activities for continuing operations was $(53,852) for the three months ended September 30, 2024, down from $(66,393) in the same period of 2023[27] - Net cash provided by financing activities was $194,717 for the six months ended September 30, 2024, compared to $(407,298) in the same period of 2023[23] Operational Challenges - Operating loss from continuing operations was $45.94 million, compared to a loss of $7.01 million in the same quarter last year, indicating a significant increase in operating losses[22] - The company reported a net loss attributable to Canopy Growth Corporation of $128.29 million, compared to a net loss of $310.01 million in the same quarter last year[22] - Canopy Growth's accumulated deficit increased to $10.59 billion from $10.33 billion, highlighting ongoing financial challenges[21] Strategic Initiatives - Canopy USA completed the acquisition of Wana Brands, enhancing brand integration and market presence[8] - The company expects to launch an innovative infused pre-roll joint product in both adult-use and medical channels in the coming weeks[5] - The company aims to accelerate entry into the U.S. cannabis market, capitalizing on growth opportunities in the sector[13] - Expectations regarding future revenues, expenses, and cash needs are being closely monitored[16] - The company is focused on expanding production and manufacturing capabilities, with associated costs and timing being evaluated[16] - Future product offerings and anticipated gross margins are under consideration as part of strategic planning[16] - The company is assessing the impacts of regulatory changes on its operations and market participation[17] - There are expectations for the successful launch and scaling of cannabis-based products in legal jurisdictions[16] - The company is evaluating the potential success and costs associated with its acquisitions and strategic alliances[17] - The ongoing impact of cannabis legalization in various jurisdictions is being analyzed for its effects on market strategy[17] Shareholder Information - Canopy USA is expected to acquire all issued and outstanding Class D subordinate voting shares of Acreage at an exchange rate of 0.045 of a Company common share for each Floating Share held[15] - The anticipated investment in Canopy USA by the Huneeus 2017 Irrevocable Trust amounts to up to $20 million[15] - The company had 93,863,960 common shares issued and outstanding as of the reporting date[21]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38496 | --- | --- | |--------------------------------------------------------------------------------------------------|----- ...

3 Marijuana Stocks For 2024 Cannabis Investors Marijuana stock investors are keeping a close eye on the sector. The reason for this is all that is occurring in the sector at this time. We have companies preparing to report earnings on top of the politics surrounding the promises of the presidential election. Politics can greatly impact trading depending on the circumstances. For instance, when a politician speaks in favor of legal cannabis, it has the potential to create a rise in trading. Due to cannabis a ...

SMITHS FALLS, ON, Oct. 25, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC) will release its financial results for the second quarter fiscal year 2025 ended September 30, 2024 before financial markets open on November 8, 2024.Following the release of its second quarter fiscal year 2025 financial results, Canopy Growth will host an audio webcast with David Klein, CEO and Judy Hong, CFO on November 8, 2024 at 10 AM Eastern Time.Webcast InformationA liv ...

The latest trading session saw Canopy Growth Corporation (CGC) ending at $5.04, denoting a +1.2% adjustment from its last day's close. The stock exceeded the S&P 500, which registered a loss of 0.92% for the day. On the other hand, the Dow registered a loss of 0.96%, and the technology-centric Nasdaq decreased by 1.6%.The the stock of company has risen by 8.26% in the past month, leading the Medical sector's loss of 4.16% and the S&P 500's gain of 2.68%.Market participants will be closely following the fina ...

SMITHS FALLS, ON, Oct. 17, 2024 /PRNewswire/ - Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (NASDAQ: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, announced today that it has made an early prepayment under its senior secured term loan (the "Term Loan") in an aggregate principal amount equal to US$100 million at a discounted price of US$97.5 million. This proactive move, which in addition to reducing the Company's leverage r ...

Canopy Growth Corporation (CGC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future. Over the past month, shares of this company have returned -15.5%, compared to the Zacks S&P 500 composite's +3.5% change. During this period, the Zacks Medical - Products industry, which Canopy Growth falls in, has lost 1%. The key question now is: What could be the stock's future dire ...

Here Are 3 Marijuana Stocks For Cannabis Investors 2024 When looking for top marijuana stocks what would a person look for or do? Like all things, you need to do your homework. Some various sectors and companies make up the cannabis industry. Progress and success can mean better gains in the market. The cannabis industry as a whole has come a long way since it first began. Now with almost every state in the US having legal cannabis operations are growing for most companies. Also, places like Canada and cert ...

● | --- | --- | |-----------------------------------------------------------------------------------------------------|-------| | | | | Canadian Gold Corp. Announces Initial Results | | | | | | from Phase 3 Drilling at Tartan Mine Extends HighGrade Mineralization to the West 7.3 gpt Gold over | | | 7.0 Metres & Discovers Potential New Zone | | October 16, 2024 7:30 AM EDT | Source: Canadian Gold Corp. Toronto, Ontario--(Newsfile Corp. - October 16, 2024) - Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or ...

In the latest market close, Canopy Growth Corporation (CGC) reached $4.14, with a -1.19% movement compared to the previous day. The stock fell short of the S&P 500, which registered a loss of 0.76% for the day. Elsewhere, the Dow saw a downswing of 0.75%, while the tech-heavy Nasdaq depreciated by 1.01%. Heading into today, shares of the company had lost 14.66% over the past month, lagging the Medical sector's loss of 3.35% and the S&P 500's gain of 4.31% in that time. The upcoming earnings release of Canop ...